NEW YORK, CARY, NC, and MONTREAL, May 21 /PRNewswire-FirstCall/ -- ICBS Limited (ICBS) (Pink Sheets :ICBT) - PharmaDerm, an international pharmaceutical venture between ICBS, McCoy Enterprises and Connell Associates, announced today that PharmaDerm will accelerate its development of Perosulin(R). Pharmaderm LLC, based in New Jersey, has developed a proprietary platform drug delivery technology for transmucosal administration of large molecule drugs as a liquid dispersion, e.g., peptides like insulin, monoclonal antibodies, hormones, vaccines and other proteins. These macro-molecular drugs cannot be administered orally and are injected, usually with a needle and syringe or by intravenous infusion. Pharmaderm LLC's oral drug delivery technology provides comparable clinical efficacy to injections. This has the potential to offer significant improvements in the quality of life (pain free, needle free therapy), with reduced side effects for diabetics and other patients. The technology incorporates the use of excipients to facilitate the absorption of large drug molecules through the mucous membranes in the buccal cavity. These excipients are approved by the FDA and are widely used in the pharmaceutical and food industries. Perosulin(R) is a needle-free, non-inhaled insulin delivery technology. The company is moving forward with the commercialization of Perosulin(R), and will be developing this needle-free platform technology and the immediate development of buccal delivery of insulin followed by pain products such as Fentanyl. "The company is focusing its efforts on equipping military and emergency personnel with a convenient, accurate, multiple-dose and needle-free atropine." Said Joe Connell, COO. "Our strategic partner, ICBS, will be working with several government and equity partners to fund the further human trials which are expected to take place in Canada" "Pharmaderm will be utilizing the Canadian government's financial assistance and grant programs for a majority of the funding necessary and we are already speaking to several groups for equity financing." Said Garth McIntosh, President & CEO of ICBS. PharmaDerm will work with the US Food and Drug Administration (FDA) and The Health Protection Branch of Canada to gain regulatory approval of Perosulin(R) for commercialization. Nb. This news release includes statements that constitute forward-looking statements. Please be aware that any such forward-looking statements are not guarantees of future performance and involve significant risks and uncertainties, and that actual results may vary materially from those in the forward-looking statements as a result of any number of factors, including the risk factors contained in the Company's disclosure documents. DATASOURCE: Inter Canadian Business Service CONTACT: Randall McCoy, President, McCoy Enterprises, http://www.mccoyllc.com/; Joseph Connell, President & CEO, (919) 342-5235, Connell Associates, http://www.connellassociates.org/; Garth McIntosh, President & CEO, (888) 932-4402, ICBS Limited, http://www.icbs.ca/

Copyright